SCHEMBL1460111

SCHEMBL1460111

CCOC(=O)CC(=O)c1ccc2ccccc2n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ PRNP P04156 1/20 0.57
▸ RAB9A P51151 4/20 0.56
▸ NPC1 O15118 3/20 0.56
▸ ALDH1A1 P00352 5/20 0.53
▸ MAPT P10636 4/20 0.53
▸ GAA P10253 1/20 0.53
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ KDM4E B2RXH2 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ MGAM O43451 1/20 0.50
▸ HDAC8 Q9BY41 1/20 0.50
▸ CYSLTR2 Q9NS75 1/20 0.48
▸ CYSLTR1 Q9Y271 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.48
▸ TP53 P04637 1/20 0.48
▸ POLB P06746 1/20 0.48
▸ KDM4C Q9H3R0 1/20 0.48
▸ ATM Q13315 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5160087 0.86 ALDH1A1 (0.58) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL8906409 0.86 ALDH1A1 (0.50) KMT2AMEN1PRNPRAB9ANPC1
SCHEMBL6858173 0.82 HDAC3 (0.47) KMT2AMEN1PRNPRAB9ANPC1
SCHEMBL30253505 0.81 KDM4E (0.64) KMT2AMEN1PRNPALDH1A1MAPT
SCHEMBL431290 0.81 KDM4E (0.64) KMT2AMEN1PRNPALDH1A1MAPT
SCHEMBL5159809 0.81 ALDH1A1 (0.51) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL4651782 0.81 ALDH1A1 (0.60) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL5070882 0.81 ALDH1A1 (0.51) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL3943579 0.80 P2RX7 (0.54) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL9664008 0.80 ALDH1A1 (0.60) KMT2AMEN1RAB9ANPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240124770-A1 COMPOUND, GUEST MATERIAL OF LIGHT-EMITTING LAYER, ORGANIC ELECTROLUMINESCENT DEVICE, AND DISPLAY DEVICE BEIJING NORMAL UNIVERSITY (CN) 2024-04-18 — — US disclosed
CN-112979713-B Compound, light-emitting layer guest material, organic electroluminescent device and display device 北京师范大学 2022-04-05 — — CN disclosed
CN-112979713-A Compound, light-emitting layer guest material, organic electroluminescent device and display device 北京师范大学 2021-06-18 — — CN disclosed
US-20130053396-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.R.L. (IT) 2013-02-28 — — US disclosed
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 — — US disclosed
EP-2480543-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS Istituto di Ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) 2012-08-01 — — EP disclosed
WO-2011036478-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2011-03-31 — — WO disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 — — EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 — — US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 — — EP disclosed
US-5616586-A Tricyclic quinoxalinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1997-04-01 — — US disclosed
EP-0642508-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1995-03-15 — — EP disclosed
WO-1993008188-A1 TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1993-04-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053396-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS SHH, SMO, GLI1 KMT2A 1680/4885MEN1 184/4885PRNP 1731/4885
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO KMT2A 1666/4885MEN1 4424/4885PRNP 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback